Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Silverback Therapeutics, Inc.
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
November 08, 2022
From
Silverback Therapeutics, Inc.
Via
GlobeNewswire
Tickers
SBTX
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
October 21, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
July 21, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
May 17, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
March 31, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
February 24, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 03, 2022
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
November 12, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Presents SBT6050-201 Trial in Progress Poster at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
November 12, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference
November 11, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
October 05, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors
September 16, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress
September 13, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
August 03, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers
July 07, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference
June 15, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics Reports First Quarter 2021 Financial Results
May 13, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference
April 08, 2021
From
Silverback Therapeutics, Inc.
Via
Business Wire
Tickers
SBTX
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.